California-headquartered biotech Genentech has agreed to pay $30 million upfront to develop immuno-oncology therapies with UK-based Bicycle Therapeutics.
Immunology-focused Vir Biotechnology and Hong Kong-based WuXi Biologics have become the latest companies to turn their focus to developing treatments for the novel coronavirus.
US-based Gilead Sciences has been granted three Chinese patents connected to possible COVID-19 treatment remdesivir, reported He Zhimin, the deputy director of China’s National Intellectual Property Administration.
French drugmaker Sanofi is looking to create a new European manufacturer of active pharmaceutical ingredients, amid concerns over dependence on a Chinese manufacturing sector hit by coronavirus.
The US Court of Appeals for the Ninth Circuit has blocked generics makers’ request to halt California’s ban on pay-for-delay deals while they challenge the legislation.
British drugmaker GSK and Chinese biotech Clover Biopharmaceuticals have partnered to develop a protein-based coronavirus vaccine candidate.
Norton Rose Fulbright has named Gina Shishima as its new US chief operations partner.
Gilead Sciences has failed in its efforts to have US government patents covering the use of HIV drugs as pre-exposure prophylaxis invalidated.
Genetic sequencing company Illumina is seeking a preliminary injunction to stop its China-based rival BGI from distributing DNA sequencers in the US.
Japanese drugmaker Kaneka has accused Irish nutrition company Glanbia of infringing two patents with its ActiQuinol antioxidant products.